Premium
The Effects of Renal Function on the Disposition of Isradipine
Author(s) -
Chandler Mary H. H.,
Schran Horst F.,
Cutler Ralph E.,
Smith Albert J.,
Gonasun Leonard M.,
Blouin Robert A.
Publication year - 1988
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1988.tb05717.x
Subject(s) - pharmacokinetics , cmax , renal function , isradipine , medicine , oral administration , endocrinology , urology , pharmacology , antagonist , receptor
The effect of renal function on isradipine kinetics was examined in four groups of subjects (N = 55) who had normal or impaired renal function. Each subject received isradipine orally as a 10‐mg capsule. Serial blood samples were obtained from 0 to 48 hours postdose and the isradipine plasma concentrations determined by radioimmunoassay. Kinetic parameters, C max , Λ 3 , t 1/2 , AUC, CL' o (oral clearance), and CL o (oral clearance standardized to body weight) were determined. Marked intersubject variability of the pharmacokinetic parameters was observed. No statistically significant differences (P > .05) were found for AUC, CL' o , and CL o parameters when renal impairment groups were compared with controls. AUC values were lower (P < .05), however, for the group with severe renal function impairment than for groups with mild or moderate renal function impairment. No significant correlations (r = –.23, P > .05; and r = .13, P > .05, respectively) were found between creatinine clearance (CL CR ) and CL o and between age and CL o . Considering the interpatient variability in isradipine disposition and the lack of significant differences in CL o between groups, no clear‐cut dosing regimen alterations, based on single‐dose data, are warranted in renal impairment .